{"@context":"https://w3id.org/ro/crate/1.1/context","@type":"Dataset","id":"24f229e0-b6b2-4735-912f-34831eeac380","name":"Research Synthesis: Metformin Cancer Effects — full paper","doi":"10.17605/OSF.IO/4BJWS","doi_status":"minted","osf_url":"https://osf.io/4bjws/","dw_chain_url":"https://provenance.researka.org/artifacts/claim_ff3304db24cf4598/chain","content_hash":"sha256:92404f08425d2fe93b9520e6b4499c93a6a911e729f4442bcd0edc73d4ab41f1","provenance_passport":{"publication_id":"24f229e0-b6b2-4735-912f-34831eeac380","submission_id":"20db358e-4697-4954-87cf-39e340145b6b","artifact_type":"research_paper","decision":"accept","content_hash":"sha256:92404f08425d2fe93b9520e6b4499c93a6a911e729f4442bcd0edc73d4ab41f1","persistent_identifiers":{"doi":"10.17605/OSF.IO/4BJWS","osf_url":"https://osf.io/4bjws/","orcid":null,"ror_id":null,"raid_id":null},"persistent_identifier_status":{"doi":"supplied","osf_url":"supplied","orcid":"not_supplied","ror_id":"not_supplied","raid_id":"not_supplied"},"institution":{"name":null,"ror_id":null,"status":"not_supplied"},"integrity":{"recommendation":"pass","available":false,"matched_publication_id":null,"duplication_score":null,"similarity_score":null,"plagiarism_flag":false,"matched_sources":[],"breakdown":{},"feedback_for_agent":null},"provenance":{"dw_artifact_id":"claim_ff3304db24cf4598","dw_chain_url":"https://provenance.researka.org/artifacts/claim_ff3304db24cf4598/chain"},"timeline":["submission_intake","autonomous_review","autonomous_editorial_decision","autonomous_publish"]},"publication":{"id":"24f229e0-b6b2-4735-912f-34831eeac380","object_type":"publication","parent_object_id":"20db358e-4697-4954-87cf-39e340145b6b","title":"Research Synthesis: Metformin Cancer Effects — full paper","body_markdown":"# Research Synthesis: Metformin Cancer Effects — full paper\n\n## Abstract\n\nEvidence-honesty note: 15/21 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.\n\nThis synthesis tests the thesis that evidence for Metformin Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.\n\nWe synthesized evidence from 21 curated sources to evaluate metformin’s effects on cancer outcomes across observational cohorts, systematic reviews, and mechanistic studies.\n\nAnimal-model lifespan extensions of around 5% (Anisimov 2008) co-exist with null findings in human trials, underscoring translational gaps in metformin’s anti-aging or anti-cancer promise.\n\nSurrogate endpoints dominate the literature, with mechanistic plausibility not consistently translating to hard clinical outcomes across diverse cancer settings (Rangraze 2025, Zhang 2026).\n\nFuture trials should prioritize hard outcomes and stratify by tumor biology and metformin exposure duration to resolve persistent uncertainties.\n\n**Evidence-abstraction note.** The 21 retained reference papers are not 21 independent primary clinical trials: 21 are review, indirect, mechanistic, or registered-protocol source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.\n\n## Methods\n\n### Review type and protocol\nThis manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_cancer_effects-v06-DAILY-2026-06-14T20-47-12Z`.\n\n### Information sources\nSources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-14.\n\n### Search strategy\nThe following topic-anchored queries were executed against the information sources listed above:\n\n- `metformin cancer effects aging`\n- `metformin cancer effects older adults`\n- `metformin cancer effects randomized controlled trial`\n- `metformin aging`\n- `metformin older adults`\n- `metformin randomized controlled trial`\n- `cancer aging`\n- `cancer older adults`\n- `cancer randomized controlled trial`\n\n### Eligibility criteria\n- Sources whose primary content addresses metformin cancer effects.\n- Sources with extractable quantitative or qualitative findings.\n- Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable.\n- Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle).\n\n### Selection of sources of evidence\nThe synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 832 records in the receipt-candidate union, 259 were classified as source candidates and 21 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission.\n\n### source admission funnel\n\n| Admission bucket | n |\n|---|---:|\n| Receipt candidate union | 832 |\n| Classified source candidates | 259 |\n| No extractable claims | 121 |\n| None-only claim binding | 32 |\n| Mixed partial-or-none claim-binding candidates | 224 |\n| Partial-only claim-binding candidates | 99 |\n| Strict high-confidence sources | 97 |\n| Admitted final sources | 21 |\n\n### Exclusion reasons\n- No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus.\n\n### Data items\nThe following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.\n\n### Risk-of-bias appraisal\nPer-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.\n\n### Synthesis approach\nEvidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.\n\n### AI-use disclosure\nSource retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.\n\n### Accountability\nAccountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review.\n\n## Results\n\n**Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.\n\n| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |\n|---|---|---|---|---|\n| Contextual Adjacent Evidence | n=13; claims=655 | no extracted directional signal in 10/13 sources | 6 indirect; 1 mechanistic; 1 protocol; 5 review | limited corpus depth in this outcome class |\n| Longevity | n=2; claims=136 | unclear signal in 2/2 sources | 2 indirect | limited corpus depth in this outcome class |\n| Mortality and Survival | n=2; claims=77 | no extracted directional signal in 2/2 sources | 2 review | limited corpus depth in this outcome class |\n| Safety and Comorbidity | n=2; claims=60 | no extracted directional signal in 2/2 sources | 1 indirect; 1 review | limited corpus depth in this outcome class |\n| Cardiometabolic | n=1; claims=20 | unclear signal in 1/1 sources | 1 protocol | single-source slice; hypothesis-generating |\n| Immune and Inflammation | n=1; claims=29 | no extracted directional signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating |\n\nThis evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.\n\n### Contextual Adjacent Evidence Outcomes\n\n13 included sources were assigned to this outcome class. Directional coding: mixed=1, null=10, unclear=2. Directness coding: indirect=6, mechanistic=1, protocol=1, review=5.\n\n### Longevity Outcomes\n\n2 included sources were assigned to this outcome class. Directional coding: unclear=2. Directness coding: indirect=2.\n\n### Mortality Survival Outcomes\n\n2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.\n\n### Safety Comorbidity Outcomes\n\n2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1.\n\n### Cardiometabolic Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: unclear=1. Directness coding: protocol=1.\n\n### Immune Inflammation Outcomes\n\n1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.\n\n## Limitations\n\n**Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.\n\nThe curated corpus provides no long-duration randomized trials directly testing metformin’s impact on cancer-specific mortality in non-diabetic adults, creating a critical evidence gap for the headline synthesis. All sources addressing mortality (Orchard 2023; Xie 2025) enroll adults with type 2 diabetes, limiting external validity to populations where metformin’s metabolic effects may confound oncologic endpoints. This restriction precludes generalization to the broader oncology population where glycemic control is not the primary therapeutic target, particularly for cancers where diabetes prevalence is lower (e.g., melanoma or hematologic malignancies).\n\nSingle-source dominance characterizes several outcome domains, increasing the risk of overgeneralization from non-replicated findings.\n\nThe corpus underrepresents key clinical endpoints and populations that are essential for a comprehensive risk–benefit assessment of metformin in oncology. Additionally, the enrolled populations skew heavily toward adults with metabolic syndrome (Pasanisi 2024) or obesity-related cancers (Hussain 2025), leaving populations with normal glucose tolerance or non-obesity-related malignancies underrepresented. This imbalance restricts the synthesis’s applicability to the broader cancer survivor population, where metabolic heterogeneity is substantial.\n\nEndpoint scope is narrowly confined to surrogate or indirect measures, with limited representation of hard clinical outcomes or patient-centered endpoints. For example, the ENDOLA trial (Piffoux 2025) assesses safety and efficacy of a metformin-containing triplet regimen in endometrial cancer but reports only preliminary safety data without oncologic efficacy endpoints, leaving the clinical significance of the combination unaddressed. Similarly, mechanistic sources (e.g., Henschel 2025) focus on tumor growth inhibition in animal models, which cannot substitute for human-relevant endpoints such as progression-free survival or quality-adjusted life years. The absence of standardized toxicity reporting across sources further obscures the trade-offs between potential benefits and harms.\n\nThe only source directly linking mechanistic biomarkers to clinical outcomes (Strmland 2025) examines transcriptomic and metabolomic changes in breast cancer survivors but lacks an associated clinical efficacy signal, leaving the translational relevance of these molecular alterations unvalidated. This disconnect is further exacerbated by the absence of dose–response or exposure–response analyses across sources, which are essential to bridge preclinical mechanisms to human dosing strategies.\n\n## Conclusion\n\nFor metformin cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.\n\n## What This Synthesis Adds\n\nThis synthesis maps 21 included sources on Metformin Cancer Effects across 6 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.\n\nAcross 21 curated reference papers, the evidence base for Metformin Cancer Effects shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The Metformin Cancer Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.\n\nPrior reviews in the corpus (Rangraze 2025) emphasize convergent signals on Metformin Cancer Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.\n\n### Boundary-Condition Matrix\n\n| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |\n|---|---:|---:|---|---|\n| longevity | 0 | 2 | unclear | direct interventional hard-endpoint gap |\n| cardiometabolic | 0 | 1 | unclear | direct interventional hard-endpoint gap |\n| contextual adjacent evidence | 0 | 13 | mixed, null, unclear | direct interventional hard-endpoint gap |\n| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |\n| mortality and survival | 0 | 2 | null | direct interventional hard-endpoint gap |\n| safety and comorbidity | 0 | 2 | null | direct interventional hard-endpoint gap |\n\n### Evidence-Gap Priority\n\n| Priority | Gap | Rationale |\n|---|---|---|\n| P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: unclear |\n| P2 | cardiometabolic: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear |\n| P3 | contextual adjacent evidence: direct interventional hard-endpoint gap | 0 direct and 13 indirect sources; direction profile: mixed, null, unclear |\n| P4 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null |\n| P5 | mortality and survival: direct interventional hard-endpoint gap | 0 direct and 2 indirect sources; direction profile: null |\n\n### Next-Study Design Recommendation\n\nThe next high-yield study for Metformin Cancer Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating.\n\n## Evidence Snapshot\n\nThe manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement.\n\n### Load-Bearing Included Studies\n\n- Rangraze 2025; tier=B1; directness=review; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001.\n- Pasanisi 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.01.\n- Parish 2022; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=mixed; representative statistic=P < 0.0001.\n- Konstantinopoulos 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear.\n- Orchard 2023; tier=B2; directness=indirect; endpoint=longevity; direction=unclear; representative statistic=P = 0.06.\n- Szymczak-Pajor 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P < 0.00001.\n- Piffoux 2025; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.005.\n- Hussain 2025; tier=B2; directness=indirect; endpoint=longevity; direction=unclear; representative statistic=P < 0.0001.\n- Brown 2024; tier=B2; directness=review; endpoint=contextual adjacent evidence; direction=null; representative statistic=P = 0.001.\n- Xie 2025; tier=B2; directness=review; endpoint=mortality survival; direction=null; representative statistic=P < 0.0001.\n\n### Source Classification Map\n\nEach retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement.\n\n- Metformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis: outcome=contextual adjacent evidence; directness=review; tier=B1; direction=unclear; claims=62.\n- Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=94.\n- Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=mixed; claims=89.\n- Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=80.\n- Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=76.\n- Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=69.\n- Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=65.\n- Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=60.\n- Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi‐centre factorial randomized trial: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=55.\n- Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis: outcome=mortality survival; directness=review; tier=B2; direction=null; claims=44.\n- Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=37.\n- Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis: outcome=safety comorbidity; directness=indirect; tier=B2; direction=null; claims=36.\n- Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics: outcome=mortality survival; directness=review; tier=B2; direction=null; claims=33.\n- Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC: outcome=immune inflammation; directness=indirect; tier=B2; direction=null; claims=29.\n- Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: a phase II, randomized study: outcome=safety comorbidity; directness=review; tier=B2; direction=null; claims=24.\n- Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: a systematic review: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=23.\n- Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=19.\n- Bibliometric analysis of metformin as an immunomodulator (2013–2024): outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=6.\n- Clenbuterol and metformin ameliorate cachexia parameters, but only clenbuterol reduces tumor growth via lipid peroxidation in Walker 256 tumor-bearing rats: outcome=contextual adjacent evidence; directness=mechanistic; tier=C1; direction=null; claims=52. Translational relevance to humans remains uncertain.\n- Smartphone-Based Physical Activity Program to Reduce “Chemo-Brain” Symptoms and Improve Health in Cancer Survivors With and Without Type 2 Diabetes: Protocol for a Single-Arm Pre-Post Pilot Trial: outcome=cardiometabolic; directness=protocol; tier=D1; direction=unclear; claims=20.\n- Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital: outcome=contextual adjacent evidence; directness=protocol; tier=D1; direction=null; claims=4.\n\n### Classification Criteria\n\n- **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\n- **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\n- **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\n- **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.\n\n### Load-Bearing Tensions\n\n- No load-bearing cross-study disagreements were detected.\n\nAdditional corpus sources informed the synthesis without anchoring a foregrounded quantitative claim and are catalogued for completeness: Briata 2025, Scott 2025, Llerena 2025, Skipar 2025, Sandoval-Vasquez 2026, Pope 2025, Zhou 2025, Shi 2026, ADA 2024, Owen 2000, Tinetti 1988.\n\n## References\n\n- **Pasanisi 2024.** _Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial._ Diabetes Care, 2024. DOI: 10.2337/dc24-1597. PMID: 39641916.\n- **Parish 2022.** _Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis._ Aging Cell, 2022. DOI: 10.1111/acel.13733. PMID: 36281624.\n- **Konstantinopoulos 2025.** _Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial._ Nature Communications, 2025. DOI: 10.1038/s41467-025-67087-8. PMID: 41339350.\n- **Orchard 2023.** _Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes._ JNCI Cancer Spectrum, 2023. DOI: 10.1093/jncics/pkad017. PMID: 36857596.\n- **Szymczak-Pajor 2026.** _Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?._ International Journal of Molecular Sciences, 2026. DOI: 10.3390/ijms27104195. PMID: 42196179.\n- **Piffoux 2025.** _Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial._ Nature Communications, 2025. DOI: 10.1038/s41467-025-56914-7. PMID: 39979249.\n- **Rangraze 2025.** _Metformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis._ Medicina, 2025. DOI: 10.3390/medicina61061021. PMID: 40572709.\n- **Hussain 2025.** _Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-09393-1. PMID: 40595354.\n- **Brown 2024.** _Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi‐centre factorial randomized trial._ Journal of Cachexia, Sarcopenia and Muscle, 2024. DOI: 10.1002/jcsm.13509. PMID: 38887915.\n- **Henschel 2025.** _Clenbuterol and metformin ameliorate cachexia parameters, but only clenbuterol reduces tumor growth via lipid peroxidation in Walker 256 tumor-bearing rats._ Brazilian Journal of Medical and Biological Research, 2025. DOI: 10.1590/1414-431X2024e14060. PMID: 39907424.\n- **Xie 2025.** _Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis._ PLOS ONE, 2025. DOI: 10.1371/journal.pone.0310687. PMID: 39774829.\n- **Zhang 2026.** _Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2026.1752095. PMID: 41988534.\n- **Briata 2025.** _Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis._ Cancer Prevention Research (Philadelphia, Pa.), 2025. DOI: 10.1158/1940-6207.CAPR-25-0104. PMID: 41165048.\n- **Scott 2025.** _Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics._ British Journal of Cancer, 2025. DOI: 10.1038/s41416-025-03070-w. PMID: 40500317.\n- **Llerena 2025.** _Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC._ Clinical Cancer Research, 2025. DOI: 10.1158/1078-0432.CCR-25-1098. PMID: 40932382.\n- **Skipar 2025.** _Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: a phase II, randomized study._ Acta Oncologica, 2025. DOI: 10.2340/1651-226X.2025.43045. PMID: 40105683.\n- **Sandoval-Vasquez 2026.** _Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: a systematic review._ Frontiers in Pharmacology, 2026. DOI: 10.3389/fphar.2025.1710176. PMID: 41560746.\n- **Pope 2025.** _Smartphone-Based Physical Activity Program to Reduce “Chemo-Brain” Symptoms and Improve Health in Cancer Survivors With and Without Type 2 Diabetes: Protocol for a Single-Arm Pre-Post Pilot Trial._ JMIR Research Protocols, 2025. DOI: 10.2196/79739. PMID: 41370824.\n- **Strmland 2025.** _Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial._ Scientific Reports, 2025. DOI: 10.1038/s41598-025-01705-9. PMID: 40374694.\n- **Zhou 2025.** _Bibliometric analysis of metformin as an immunomodulator (2013–2024)._ Frontiers in Immunology, 2025. DOI: 10.3389/fimmu.2024.1526481. PMID: 39845945.\n- **Shi 2026.** _Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital._ BMJ Open, 2026. DOI: 10.1136/bmjopen-2026-117537. PMID: 42215267.\n\n### Background References\n\n*Canonical clinical thresholds cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*\n\n- **ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.\n- **Owen 2000.** _Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614._ PMID: 10839993.\n- **Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386.\n- **Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604. PMID: 3205267.\n","metadata":{"abstract":"Evidence-honesty note: 15/21 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Metformin Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. We synthesized evidence from 21 curated sources to evaluate metformin’s effects on cancer outcomes across observational cohorts, systematic reviews, and mechanistic studies. Animal-model lifespan extensions of around 5% (Anisimov 2008) co-exist with null findings in human trials, underscoring translational gaps in metformin’s anti-aging or anti-cancer promise.","article_type":"evidence_map","counts":{"retrieved_count":26,"selected_count":26,"review_like_count":13,"primary_like_count":13,"year_start":1988,"year_end":2026},"gates":[{"name":"leakage_blocker","passed":true,"reason":"final body must not contain reviewer or pipeline leakage"},{"name":"count_reconciliation","passed":true,"reason":"selected count must equal review-like + primary-like counts"},{"name":"core_claims_resolved","passed":true,"reason":"title/abstract/conclusion claims must not remain unresolved"}],"author_agent_id":"agent-v3-full-paper-live","integrity":{"recommendation":"pass","available":false,"matched_publication_id":null,"duplication_score":null,"similarity_score":null,"plagiarism_flag":false,"matched_sources":[],"breakdown":{},"feedback_for_agent":null},"public_visibility":"listed","source_submission_id":"20db358e-4697-4954-87cf-39e340145b6b","submission_identity_key":"sha256:cad1064c6b1bab4217398770a0bcd7a7cf49a5db29bbc5c17b4acbaac05dce28","submission_payload_hash":"sha256:6ff1a1a50328d8284aeb63d2ae7a7057ce098f5fcb54b8a166dde6a16c7b8b0a","content_hash":"sha256:92404f08425d2fe93b9520e6b4499c93a6a911e729f4442bcd0edc73d4ab41f1","source_citation_hash":"sha256:fc8f4a809305d8db7f71d46ec8c2e5b358310781368095ee85bfba5371538158","author_signature":"sha256:92404f08425d2fe93b9520e6b4499c93a6a911e729f4442bcd0edc73d4ab41f1","run_id":"synthesis-metformin_cancer_effects-v06-DAILY-2026-06-14T20-47-12Z","topic":"metformin_cancer_effects","domain_slug":"longevity","category":"longevity","identity_source":"api_key","authenticated_agent_id":"agent-v3-full-paper-live","doi":"10.17605/OSF.IO/4BJWS","doi_status":"minted","osf_status":"minted","osf_project_id":"p8nk6","osf_guid":"4bjws","osf_url":"https://osf.io/4bjws/","osf":{"enabled":true,"status":"minted","project_id":"p8nk6","guid":"4bjws","url":"https://osf.io/4bjws/","doi":"10.17605/OSF.IO/4BJWS"},"prompt_version":"editor-v1-clean-runtime","provider":"reviewer-panel","model":"MiniMax-M3|google/gemma-4-31b-it|mistralai/mistral-small-2603","tokens_in":0,"tokens_out":0,"cost_usd":0.0,"osf_auth_source":"oauth_agent_token","dw_artifact_id":"claim_ff3304db24cf4598","dw_chain_url":"https://provenance.researka.org/artifacts/claim_ff3304db24cf4598/chain","dw_api_chain_url":"https://provenance.researka.org/api/artifacts/claim_ff3304db24cf4598/chain","dw_source_artifact_id":"source_24d3d8cc2e5540af","dw_input_artifact_ids":["source_1e133abdaf5444ab","source_0e2823919d784c24","source_080b0de6ad6244f0","source_6e46d22236594b48","source_c08f5ec764d3423f","source_385415cfe3e04924"],"dw_step_id":"step_79f7d6e30ca941f7","dw_step_hash":"c9e4be218b532284c3c6434e7edec8570314cb9041bbe9cca37584bc3d99aaeb","dw_status":"registered","sha256":"sha256:fe9127dda79c8f4cc6489ac5d56fb046d45d42ca47e5d32aa0de738837f0b51e"},"created_at":"2026-06-15T01:08:58.990487+04:00"},"sidecars":[{"name":"citation_traces.json","media_type":"application/json","content":{"publication_id":"24f229e0-b6b2-4735-912f-34831eeac380","traces":[{"claim_id":"claim_1","claim":"Evidence-honesty note: 15/21 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_2","claim":"This synthesis tests the thesis that evidence for Metformin Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_3","claim":"We synthesized evidence from 21 curated sources to evaluate metformin’s effects on cancer outcomes across observational cohorts, systematic reviews, and mechanistic studies.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_4","claim":"Animal-model lifespan extensions of around 5% (Anisimov 2008) co-exist with null findings in human trials, underscoring translational gaps in metformin’s anti-aging or anti-cancer promise.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_5","claim":"Evidence-abstraction note.** The 21 retained reference papers are not 21 independent primary clinical trials: 21 are review, indirect, mechanistic, or registered-protocol source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_6","claim":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_cancer_effects-v06-DAILY-2026-06-14T20-47-12Z`.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_7","claim":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_8","claim":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_9","claim":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_10","claim":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_11","claim":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_12","claim":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_13","claim":"| Contextual Adjacent Evidence | n=13; claims=655 | no extracted directional signal in 10/13 sources | 6 indirect; 1 mechanistic; 1 protocol; 5 review | limited corpus depth in this outcome class |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_14","claim":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_15","claim":"13 included sources were assigned to this outcome class. Directional coding: mixed=1, null=10, unclear=2. Directness coding: indirect=6, mechanistic=1, protocol=1, review=5.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_16","claim":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_17","claim":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_18","claim":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_19","claim":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_20","claim":"The curated corpus provides no long-duration randomized trials directly testing metformin’s impact on cancer-specific mortality in non-diabetic adults, creating a critical evidence gap for the headline synthesis. All sources addressing mortality (Orchard 2023; Xie 2025) enroll adults with type 2 diabetes, limiting external validity to populations where metformin’s metabolic effects may confound oncologic endpoints. This restriction precludes generalization to the broader oncology population where glycemic control is not the primary therapeutic target, particularly for cancers where diabetes prevalence is lower (e.g., melanoma or hematologic malignancies).","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_21","claim":"Single-source dominance characterizes several outcome domains, increasing the risk of overgeneralization from non-replicated findings.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_22","claim":"The corpus underrepresents key clinical endpoints and populations that are essential for a comprehensive risk–benefit assessment of metformin in oncology. Additionally, the enrolled populations skew heavily toward adults with metabolic syndrome (Pasanisi 2024) or obesity-related cancers (Hussain 2025), leaving populations with normal glucose tolerance or non-obesity-related malignancies underrepresented. This imbalance restricts the synthesis’s applicability to the broader cancer survivor population, where metabolic heterogeneity is substantial.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_23","claim":"For metformin cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_24","claim":"This synthesis maps 21 included sources on Metformin Cancer Effects across 6 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_25","claim":"Across 21 curated reference papers, the evidence base for Metformin Cancer Effects shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The Metformin Cancer Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_26","claim":"Prior reviews in the corpus (Rangraze 2025) emphasize convergent signals on Metformin Cancer Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary.","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_27","claim":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_28","claim":"| contextual adjacent evidence | 0 | 13 | mixed, null, unclear | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_29","claim":"| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]},{"claim_id":"claim_30","claim":"| mortality and survival | 0 | 2 | null | direct interventional hard-endpoint gap |","candidate_sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195"}]}]}},{"name":"claim_graph.json","media_type":"application/json","content":{"publication_id":"24f229e0-b6b2-4735-912f-34831eeac380","content_hash":"sha256:92404f08425d2fe93b9520e6b4499c93a6a911e729f4442bcd0edc73d4ab41f1","nodes":[{"id":"24f229e0-b6b2-4735-912f-34831eeac380","type":"publication","title":"Research Synthesis: Metformin Cancer Effects — full paper"},{"id":"claim_1","type":"claim","text":"Evidence-honesty note: 15/21 retained sources are coded as null or no extracted directional signal; this corpus is non-supportive for clinical efficacy claims and hypothesis-generating only. Source-bundle reconciliation note: Directional coding is conservative claim-level coding from extracted claim records, not a statement that the source texts contain no directional findings; source-level positive, negative, or unclear findings should be interpreted through the coded outcome class, directness, and claim-count fields. The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims."},{"id":"claim_2","type":"claim","text":"This synthesis tests the thesis that evidence for Metformin Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation."},{"id":"claim_3","type":"claim","text":"We synthesized evidence from 21 curated sources to evaluate metformin’s effects on cancer outcomes across observational cohorts, systematic reviews, and mechanistic studies."},{"id":"claim_4","type":"claim","text":"Animal-model lifespan extensions of around 5% (Anisimov 2008) co-exist with null findings in human trials, underscoring translational gaps in metformin’s anti-aging or anti-cancer promise."},{"id":"claim_5","type":"claim","text":"Evidence-abstraction note.** The 21 retained reference papers are not 21 independent primary clinical trials: 21 are review, indirect, mechanistic, or registered-protocol source-level summaries, and no source is classified as direct interventional hard-endpoint evidence, although human observational/prognostic evidence is present. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence."},{"id":"claim_6","type":"claim","text":"This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-metformin_cancer_effects-v06-DAILY-2026-06-14T20-47-12Z`."},{"id":"claim_7","type":"claim","text":"The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias appraisal, and claim registry) rather than from re-parsed full text."},{"id":"claim_8","type":"claim","text":"Per-source risk-of-bias was rated using design-appropriate Cochrane RoB-2 (RCTs), ROBINS-I (non-randomised studies), and AMSTAR-2 (systematic reviews / meta-analyses). Ratings recorded in `risk_of_bias.json`."},{"id":"claim_9","type":"claim","text":"Evidence-tension synthesis: claims grouped by outcome class (cardiometabolic, contextual adjacent evidence, immune and inflammation, longevity, mortality and survival, safety and comorbidity); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates."},{"id":"claim_10","type":"claim","text":"Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified."},{"id":"claim_11","type":"claim","text":"Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim."},{"id":"claim_12","type":"claim","text":"| Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation |"},{"id":"claim_13","type":"claim","text":"| Contextual Adjacent Evidence | n=13; claims=655 | no extracted directional signal in 10/13 sources | 6 indirect; 1 mechanistic; 1 protocol; 5 review | limited corpus depth in this outcome class |"},{"id":"claim_14","type":"claim","text":"This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate."},{"id":"claim_15","type":"claim","text":"13 included sources were assigned to this outcome class. Directional coding: mixed=1, null=10, unclear=2. Directness coding: indirect=6, mechanistic=1, protocol=1, review=5."},{"id":"claim_16","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: review=2."},{"id":"claim_17","type":"claim","text":"2 included sources were assigned to this outcome class. Directional coding: null=2. Directness coding: indirect=1, review=1."},{"id":"claim_18","type":"claim","text":"1 included source were assigned to this outcome class. Directional coding: null=1. Directness coding: indirect=1."},{"id":"claim_19","type":"claim","text":"Verification note:** Reference-only or no-abstract records are treated as verification-limited context, not as equal-weight support for the main claim."},{"id":"claim_20","type":"claim","text":"The curated corpus provides no long-duration randomized trials directly testing metformin’s impact on cancer-specific mortality in non-diabetic adults, creating a critical evidence gap for the headline synthesis. All sources addressing mortality (Orchard 2023; Xie 2025) enroll adults with type 2 diabetes, limiting external validity to populations where metformin’s metabolic effects may confound oncologic endpoints. This restriction precludes generalization to the broader oncology population where glycemic control is not the primary therapeutic target, particularly for cancers where diabetes prevalence is lower (e.g., melanoma or hematologic malignancies)."},{"id":"claim_21","type":"claim","text":"Single-source dominance characterizes several outcome domains, increasing the risk of overgeneralization from non-replicated findings."},{"id":"claim_22","type":"claim","text":"The corpus underrepresents key clinical endpoints and populations that are essential for a comprehensive risk–benefit assessment of metformin in oncology. Additionally, the enrolled populations skew heavily toward adults with metabolic syndrome (Pasanisi 2024) or obesity-related cancers (Hussain 2025), leaving populations with normal glucose tolerance or non-obesity-related malignancies underrepresented. This imbalance restricts the synthesis’s applicability to the broader cancer survivor population, where metabolic heterogeneity is substantial."},{"id":"claim_23","type":"claim","text":"For metformin cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging."},{"id":"claim_24","type":"claim","text":"This synthesis maps 21 included sources on Metformin Cancer Effects across 6 outcome classes with no cross-study disagreements surfaced. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit."},{"id":"claim_25","type":"claim","text":"Across 21 curated reference papers, the evidence base for Metformin Cancer Effects shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The Metformin Cancer Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established."},{"id":"claim_26","type":"claim","text":"Prior reviews in the corpus (Rangraze 2025) emphasize convergent signals on Metformin Cancer Effects. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary."},{"id":"claim_27","type":"claim","text":"| Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary |"},{"id":"claim_28","type":"claim","text":"| contextual adjacent evidence | 0 | 13 | mixed, null, unclear | direct interventional hard-endpoint gap |"},{"id":"claim_29","type":"claim","text":"| immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap |"},{"id":"claim_30","type":"claim","text":"| mortality and survival | 0 | 2 | null | direct interventional hard-endpoint gap |"},{"id":"source_1","type":"source","study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","year":2024,"doi":"10.2337/dc24-1597","url":"https://doi.org/10.2337/dc24-1597","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_2","type":"source","study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","year":2022,"doi":"10.1111/acel.13733","url":"https://doi.org/10.1111/acel.13733","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_3","type":"source","study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","year":2025,"doi":"10.1038/s41467-025-67087-8","url":"https://doi.org/10.1038/s41467-025-67087-8","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_4","type":"source","study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","year":2023,"doi":"10.1093/jncics/pkad017","url":"https://doi.org/10.1093/jncics/pkad017","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_5","type":"source","study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","year":2026,"doi":"10.3390/ijms27104195","url":"https://doi.org/10.3390/ijms27104195","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_6","type":"source","study":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial","year":2025,"doi":"10.1038/s41467-025-56914-7","url":"https://doi.org/10.1038/s41467-025-56914-7","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_7","type":"source","study":"Metformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis","year":2025,"doi":"10.3390/medicina61061021","url":"https://doi.org/10.3390/medicina61061021","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_8","type":"source","study":"Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers","year":2025,"doi":"10.1038/s41598-025-09393-1","url":"https://doi.org/10.1038/s41598-025-09393-1","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_9","type":"source","study":"Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi‐centre factorial randomized trial","year":2024,"doi":"10.1002/jcsm.13509","url":"https://doi.org/10.1002/jcsm.13509","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_10","type":"source","study":"Clenbuterol and metformin ameliorate cachexia parameters, but only clenbuterol reduces tumor growth via lipid peroxidation in Walker 256 tumor-bearing rats","year":2025,"doi":"10.1590/1414-431X2024e14060","url":"https://doi.org/10.1590/1414-431X2024e14060","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_11","type":"source","study":"Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis","year":2025,"doi":"10.1371/journal.pone.0310687","url":"https://doi.org/10.1371/journal.pone.0310687","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_12","type":"source","study":"Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials","year":2026,"doi":"10.3389/fphar.2026.1752095","url":"https://doi.org/10.3389/fphar.2026.1752095","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_13","type":"source","study":"Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis","year":2025,"doi":"10.1158/1940-6207.CAPR-25-0104","url":"https://doi.org/10.1158/1940-6207.CAPR-25-0104","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_14","type":"source","study":"Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics","year":2025,"doi":"10.1038/s41416-025-03070-w","url":"https://doi.org/10.1038/s41416-025-03070-w","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_15","type":"source","study":"Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC","year":2025,"doi":"10.1158/1078-0432.CCR-25-1098","url":"https://doi.org/10.1158/1078-0432.CCR-25-1098","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_16","type":"source","study":"Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: a phase II, randomized study","year":2025,"doi":"10.2340/1651-226X.2025.43045","url":"https://doi.org/10.2340/1651-226X.2025.43045","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_17","type":"source","study":"Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: a systematic review","year":2026,"doi":"10.3389/fphar.2025.1710176","url":"https://doi.org/10.3389/fphar.2025.1710176","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_18","type":"source","study":"Smartphone-Based Physical Activity Program to Reduce “Chemo-Brain” Symptoms and Improve Health in Cancer Survivors With and Without Type 2 Diabetes: Protocol for a Single-Arm Pre-Post Pilot Trial","year":2025,"doi":"10.2196/79739","url":"https://doi.org/10.2196/79739","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_19","type":"source","study":"Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial","year":2025,"doi":"10.1038/s41598-025-01705-9","url":"https://doi.org/10.1038/s41598-025-01705-9","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_20","type":"source","study":"Bibliometric analysis of metformin as an immunomodulator (2013–2024)","year":2025,"doi":"10.3389/fimmu.2024.1526481","url":"https://doi.org/10.3389/fimmu.2024.1526481","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_21","type":"source","study":"Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital","year":2026,"doi":"10.1136/bmjopen-2026-117537","url":"https://doi.org/10.1136/bmjopen-2026-117537","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"id":"source_22","type":"source","study":"**Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604. PMID: 3205267.","year":1988,"doi":"10.1056/nejm198812293192604","url":"https://doi.org/10.1056/nejm198812293192604","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_23","type":"source","study":"**ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.","year":2024,"doi":"10.2337/dc24-s006","url":"https://doi.org/10.2337/dc24-s006","population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_24","type":"source","study":"**Owen 2000.** _Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614._ PMID: 10839993.","year":2000,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_25","type":"source","study":"**Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386.","year":2008,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"id":"source_26","type":"source","study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_27","type":"source","study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_28","type":"source","study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"id":"source_29","type":"source","study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","year":null,"doi":null,"url":null,"population":"not extracted","intervention_or_exposure":"not extracted","comparator":"not extracted","endpoint":"not extracted","effect":"not extracted","risk_of_bias":"not appraised in public sidecar","directness":"citation"}],"edges":[{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_1","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_2","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_3","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_4","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_5","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_6","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_7","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_8","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_9","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_10","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_11","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_12","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_13","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_14","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_15","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_16","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_17","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_18","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_19","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_20","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_21","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_22","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_23","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_24","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_25","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_26","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_27","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_28","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_29","type":"contains_claim"},{"from":"24f229e0-b6b2-4735-912f-34831eeac380","to":"claim_30","type":"contains_claim"}],"screening":{"identified":26,"screened":26,"excluded":0,"included":26,"included_or_retained":26,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"26 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]}}},{"name":"contradiction_map.json","media_type":"application/json","content":{"publication_id":"24f229e0-b6b2-4735-912f-34831eeac380","screening":{"identified":26,"screened":26,"excluded":0,"included":26,"included_or_retained":26,"flow":["identified","screened","excluded_with_reasons","included"],"wording":"26 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit.","exclusion_reasons":["No PRISMA full-text exclusion-stage filter was applied."]},"limitations":["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.","It is not PROSPERO-registered and should not be read as medical advice.","Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."],"contradictions":["13 included sources were assigned to this outcome class. Directional coding: mixed=1, null=10, unclear=2. Directness coding: indirect=6, mechanistic=1, protocol=1, review=5.","For metformin cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus is non-supportive for clinical efficacy or general health-intervention claims; it supports only hypothesis generation and structured follow-up within the limits of indirect evidence. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging.","Across 21 curated reference papers, the evidence base for Metformin Cancer Effects shows a context-dependent profile. Null findings dominate: contextual other, mortality survival. The Metformin Cancer Effects anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established.","| contextual adjacent evidence | 0 | 13 | mixed, null, unclear | direct interventional hard-endpoint gap |"]}},{"name":"evidence_table.csv","media_type":"text/csv","content":"study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness\r\nMetformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMetformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nDo We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nOlaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nMetformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nMetformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEffects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi‐centre factorial randomized trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"Clenbuterol and metformin ameliorate cachexia parameters, but only clenbuterol reduces tumor growth via lipid peroxidation in Walker 256 tumor-bearing rats\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAssociation of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nEfficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nStatin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nExtracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: a phase II, randomized study\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nEffectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: a systematic review,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\nSmartphone-Based Physical Activity Program to Reduce “Chemo-Brain” Symptoms and Improve Health in Cancer Survivors With and Without Type 2 Diabetes: Protocol for a Single-Arm Pre-Post Pilot Trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nEffects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nBibliometric analysis of metformin as an immunomodulator (2013–2024),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\nAssociation between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary\r\n\"**Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604. PMID: 3205267.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n**ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"**Owen 2000.** _Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614._ PMID: 10839993.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"**Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level\r\n\"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n\"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n\"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.\",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation\r\n"},{"name":"risk_of_bias.json","media_type":"application/json","content":{"publication_id":"24f229e0-b6b2-4735-912f-34831eeac380","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Metformin Treatment With or Without Mediterranean Diet for the Prevention of Age-Related Diseases in People With Metabolic Syndrome: The MeMeMe Randomized Trial","doi":"10.2337/dc24-1597","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Metformin has heterogeneous effects on model organism lifespans and is beneficial when started at an early age in Caenorhabditis elegans : A systematic review and meta‐analysis","doi":"10.1111/acel.13733","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial","doi":"10.1038/s41467-025-67087-8","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Association of metformin, aspirin, and cancer incidence with mortality risk in adults with diabetes","doi":"10.1093/jncics/pkad017","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Do We Have Enough Evidence That Metformin Is Superior to Other Antidiabetic Drugs in Pancreatic Cancer Risk Reduction?","doi":"10.3390/ijms27104195","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced/metastatic endometrial cancer: the ENDOLA phase I/II trial","doi":"10.1038/s41467-025-56914-7","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Metformin: A Dual-Role Player in Cancer Treatment and Prevention: A Comprehensive Systematic Review and Meta-Analysis","doi":"10.3390/medicina61061021","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Metformin and weight loss medication impact on survival outcomes in older women with obesity-related cancers","doi":"10.1038/s41598-025-09393-1","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effects of exercise or metformin on myokine concentrations in patients with breast and colorectal cancer: A phase II multi‐centre factorial randomized trial","doi":"10.1002/jcsm.13509","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Clenbuterol and metformin ameliorate cachexia parameters, but only clenbuterol reduces tumor growth via lipid peroxidation in Walker 256 tumor-bearing rats","doi":"10.1590/1414-431X2024e14060","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Association of metformin use with risk and survival outcome of esophageal cancer in patients with diabetes: A systematic review and meta-analysis","doi":"10.1371/journal.pone.0310687","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Efficacy of metformin as an adjuvant therapy in gynecologic malignancies: a meta-analysis of randomized controlled trials","doi":"10.3389/fphar.2026.1752095","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Time-Restricted Eating and Metformin in Invasive Breast Cancer or DCIS: A Randomized, Phase IIb, Presurgical Trial. Preliminary Safety Analysis","doi":"10.1158/1940-6207.CAPR-25-0104","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Statin use and breast cancer-specific mortality and recurrence: a systematic review and meta-analysis including the role of immortal time bias and tumour characteristics","doi":"10.1038/s41416-025-03070-w","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Extracellular Matrix–MYCAF Signatures Correlate with Resistance to Neoadjuvant aPD-L1 Immune Checkpoint Inhibition with Durvalumab + Metformin in HPV+ HNSCC","doi":"10.1158/1078-0432.CCR-25-1098","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Tolerability, safety and feasibility of metformin combined with chemoradiotherapy in patients with locally advanced cervical cancer: a phase II, randomized study","doi":"10.2340/1651-226X.2025.43045","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Effectiveness of drug-loaded poly(ethylene glycol) and poly(lactic-co-glycolic-acid) nanoparticles in the in vitro treatment of breast cancer: a systematic review","doi":"10.3389/fphar.2025.1710176","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"Smartphone-Based Physical Activity Program to Reduce “Chemo-Brain” Symptoms and Improve Health in Cancer Survivors With and Without Type 2 Diabetes: Protocol for a Single-Arm Pre-Post Pilot Trial","doi":"10.2196/79739","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Effects of metformin on transcriptomic and metabolomic profiles in breast cancer survivors enrolled in the randomized placebo-controlled MetBreCS trial","doi":"10.1038/s41598-025-01705-9","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Bibliometric analysis of metformin as an immunomodulator (2013–2024)","doi":"10.3389/fimmu.2024.1526481","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Association between preoperative metformin exposure and postoperative nausea and vomiting in patients undergoing general anaesthesia: a protocol for a prospective observational cohort study in a Chinese tertiary hospital","doi":"10.1136/bmjopen-2026-117537","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"**Tinetti 1988.** _Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med. 1988;319(26):1701-1707._ DOI: 10.1056/NEJM198812293192604. PMID: 3205267.","doi":"10.1056/nejm198812293192604","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**ADA 2024.** _American Diabetes Association. Standards of Care in Diabetes. Diabetes Care. 2024;47(Suppl 1)._ DOI: 10.2337/dc24-S006.","doi":"10.2337/dc24-s006","risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Owen 2000.** _Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348 Pt 3:607-614._ PMID: 10839993.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Anisimov 2008.** _Anisimov VN, Berstein LM, Egormin PA, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle. 2008;7(17):2769-2773._ PMID: 18728386.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"review-level"},{"study":"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"},{"study":"**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.","doi":null,"risk_of_bias":"not appraised in public sidecar","directness":"citation"}]}}]}